ArticleParasites & vectors2020
Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio
Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Increased metallopeptidase activity, compromised endothelial integrity and impaired pathogen recognition revealed by transcriptomics inCurrent research in parasitology & vector-borne diseases · 2026Article
- Epidemiological Mapping of Canine Angiostrongylosis in Portugal: Findings from a Nationwide Prevalence Survey.Veterinary sciences · 2025Article
- Successful Removal ofPathogens (Basel, Switzerland) · 2023Article
- Hemostatic Dysfunction in Dogs Naturally Infected withPathogens (Basel, Switzerland) · 2022Review
- Review
- Simultaneous Exposure toPathogens (Basel, Switzerland) · 2021Article
- New Insights Into Pathogenesis, Diagnostics, and Therapeutic Options for Canine Angiostrongylosis.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio
methodsPrevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated.
resultsIn the prevention study, there were no adverse events related to treatment with Simparica Trio
conclusionsMonthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.